Etomoxir: Difference between revisions
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
'''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation. | '''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation. | ||
'''Preparation of | '''Preparation of 10 mM stock solution''' (dissolved in H<sub>2</sub>O): | ||
::1) Weigh ... | ::1) Weigh 5 mg etomoxir. | ||
::2) Add 1.476 mL dt H<sub>2</sub>O. | |||
::3) Divide into 500 µL portions. | |||
::4) Store frozen at -20 °C. | |||
Revision as of 09:39, 2 May 2018
- high-resolution terminology - matching measurements at high-resolution
Etomoxir
Description
Etomoxir (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Eto inhibits the transport of the long-chain fatty acids from the cytosol into the mitochondrial matrix, thereby blocking the formation of acyl carnitines in the cytosol, leading finally to inhibition of the fatty acid oxidation. Of note, in contrast to long-chain fatty acids, the transport of short- and medium chain fatty acids is carnitine-independent. The commercially available white compound is soluble in water.
Abbreviation: Eto
MitoPedia topics:
Inhibitor
Application in HRFR
Eto (Etomoxir): ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; FW= 338.76
Caution: Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.
Preparation of 10 mM stock solution (dissolved in H2O):
- 1) Weigh 5 mg etomoxir.
- 2) Add 1.476 mL dt H2O.
- 3) Divide into 500 µL portions.
- 4) Store frozen at -20 °C.
